The sudden departure of Peter Marks, MD, from the FDA has prompted a chorus of criticism and despair from industry leaders and trade organizations.
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback